

## Publications Florence Maschat

### Articles

- Marelli, C., Maschat, F. (2016). [P42: a novel and promising peptide-based therapy for Huntington's disease](#). *Orphanet Journal of Rare Diseases*. 11:24. DOI: 10.1186/s13023-016-0405-3
- Arribat, Y., Talmat-Amar, Y., Paucard, A., Lesport, P., Bauer, C., Bec, N., Parmentier, ML., Benigno, L., Larroque, C., Maurel, P., Maschat, F. (2014). [Systemic delivery of P42 peptide: a new weapon to fight Huntington's disease](#). *Acta Neuropathologica Communications* (2):86-103.
- Arribat, Y., Bonneaud, N., Talmat-Amar, Y., Layalle, S., Parmentier, M. L., Maschat, F. (2013). [A Huntingtin Peptide Inhibits PolyQ-Huntingtin Associated Defects](#). *PLoS One* 8(7): e68775
- Layalle, S., Volovitch, M. Mugat, B. Bonneaud, N. Parmentier, ML., Prochiantz A., Joliot, A., Maschat, F. (2011). [Engrailed homeoprotein acts as a signaling molecule in the developing fly](#). *Development* 138:2315-2323. Evaluation dans le top 2% (Faculty of 1000: 2011. F1000.com/10832956).
- Godin JD, Poizat G, Hickey MA, Maschat F, Humbert S. (2010) [Mutant huntingtin-impaired degradation of beta-catenin causes neurotoxicity in Huntington's disease](#). *EMBO J*. Jul 21;29(14):2433-45.
- Mugat, B., Parmentier, M-L, Bonneaud, N., Chan H.O.E, Maschat, F. (2008) [Protective role of Engrailed in a \*Drosophila\* model of Huntington's disease](#). *Human Molecular Genetics*, 17(22), 3601- 3616; doi:10.1093/hmg/ddn255.
- Colomb S, Joly W, Bonneaud N, Maschat F (2008) [A Concerted Action of Engrailed and Gooseberry-Neuro in Neuroblast 6-4 Is Triggering the Formation of Embryonic Posterior Commissure Bundles](#). *PLoS ONE* 3(5): e2197. doi:10.1371/journal.pone.0002197
- Joly, W., Mugat, B., Maschat, F. (2007) [Engrailed controls the organisation of the ventral nerve cord through frazzled regulation](#). *Developmental Biology*. 301, 542-554.
- Girard F., Savare J., Bonneaud N., Joly W., Ferraz, C., Maschat F. (2006) [Chromatin immunoprecipitation reveals a novel role for the \*Drosophila\* SoxNeuro transcription factor in axonal patterning](#). *Developmental Biology*. 299, 530-542.
- Chanas, G, Maschat, F. (2005) Tissue specificity of *hedgehog* repression by the Polycomb group during *Drosophila melanogaster* development. *Mechanisms of Development*. 122, 975-987.
- Chanas, G., Lavrov, S., Iral, F., Cavalli, G., Maschat, F. (2004) *engrailed* and *polyhomeotic* maintain Posterior cell identity through *cubitus-interruptus* regulation. *Developmental Biology*. 272, 522-535.
- Solano, P., Mugat, B., Martin, D., Girard, F., Huibant, J.M., Ferraz, C., Jacq, B., Demaille, J., Maschat, F. (2003) [Genome-wide identification of in vivo \*Drosophila\* Engrailed-binding DNA fragments and related target genes](#). *Development*. 130, 1243-1254.
- Maschat, F (2001) Isolation of Homeodomain Engrailed Target Genes by UV Cross-Linking and Chromatin IP. In Mapping Protein/DNA Interactions by Cross-

Linking. Paris: Institut national de la santé et de la recherche médicale.

- Randsholt, N., Maschat, F., Santamaria, P. (2000) *polyhomeotic* controls *engrailed* expression and the *hedgehog* signaling pathway in imaginal discs. *Mechanisms of Development*. 95, 89-99.
- Maschat, F. (1999) *Engrailed* gene. In The Encyclopedia of Molecular Biology. (T. E. Creighton, ed.). John Wiley & Sons. New-York. Volume 2 pp 819-823.
- Maschat, F., Serrano, N., Randsholt, N. et Géraud, G. (1998) *engrailed* and *polyhomeotic* interactions are required to maintain the A/P boundary of the *Drosophila* developing wing. *Development*. 125. 2771-2780.
- Serrano, N., Maschat, F. (1998) Molecular mechanism of *polyhomeotic* activation by *Engrailed*. *EMBO. J*, 17, 3704-3713.
- Serrano, N., Brock, H.W., Maschat, F. (1997)  $\beta$ 3-*tubulin* is directly repressed by the *Engrailed* protein in *Drosophila*. *Development*, 124, 2527-2536.
- Saenz-Robles, M. T., Maschat, F., Tabata, T., Scott, M. P., Kornberg, T. (1995) Selection and characterization of sequences with high affinity for the engrailed protein of *Drosophila*. *Mechanisms of Development*, 53, 185-195.
- Serrano, N., Brock, H.W., Demeret, C., Dura, J.M., Randsholt, N.B., Kornberg, T., Maschat, F. (1995) *polyhomeotic* appears to be a target of *Engrailed* regulation in *Drosophila*. *Development*., 121, 1691-1703.
- Maschat, F., Dubertret, M.L., Lepesant, J-A. (1991) Mapping of essential sequences for a correct developmental regulation of the ecdysterone inducible P1 gene of *Drosophila*. *Molecular and cellular Biology*, 11, 2913-2917.
- Maschat, F., Dubertret, M.L., Therond, P., Claverie, J.M., Lepesant, J-A. (1990) Structure of the P1 gene, an ecdysone inducible gene of *Drosophila melanogaster*. *J. Mol. Biol.*, 214, 359-372.
- Deutsch, J, Laval, M, Lepesant, J.A., Maschat, F., Pourrain, F. Rat, L. (1989) Larval Fat body specific gene expression in *D melanogaster*. *Developmental genetics*, 10, 220-231.
- Maschat, F. (1987) Analyse de la structure et des séquences de régulation d'un gène induit par l'ecdysone chez *Drosophila melanogaster*. Thèse de Doctorat d'Etat ès sciences, Université Paris VII.
- Maschat, F., Roux, J., Benes, H., Pictet, R., Jami, J., Lepesant, J-A. (1986) Hormonal and developmental specificities of transcription lie within a 1.5 kb region 5' to the *Drosophila* P1 gene. *EMBO J.*, 5, 583-588.
- Lepesant, J-A., Maschat, F., Kejzlarova-Lepesant, J., Benes, H., Yanicostas, C. (1986) Developmental and ecdysteroid regulation of gene expression in the larval fat body of *D. melanogaster*. *Arch. Insect. Biochem. Physiol.* 133-141.
- Cherbas et al. (Je suis un des auteurs parmi 27) (1986) Structural and functional analysis of some moulting hormone responsive genes from *Drosophila*. *Insect Biochem*, 16, 241-248.
- Lepesant, J-A., Maschat, F., Kejzlarova-Lepesant, J. (1983) Ecdysteroid regulated gene expression in *Drosophila melanogaster*. The fat body system. In: *Hormones and Cell Regulation*, J.E. Dumont, J. Nunez, R.M. Denton, eds, Elsevier Biomedical Press, 7, pp. 255-268.

- Moreau, J., Marcaud, L., Maschat, F., Kejzlarova-Lepesant, J., Lepesant, J-A., Scherrer, K. (1982) A+T rich linkers define functional domains in eukaryotic DNA. *Nature* , 295, 260-262.
- Maschat, F. (1981) Organisation du gène de structure d'une protéine induite par l'ecdysone chez *Drosophila melanogaster*. Thèse de Doctorat de Troisième Cycle, Université Paris VII.
- Lepesant, J-A., Kejzlarova-Lepesant, J., Maschat, F., Rat, L., Martin-Somme, G. (1981) Expression and structure of an ecdysterone inducible gene in *Drosophila melanogaster*. In: *Regulation of Insect Development and Behavior*, pp. 703-712.
- Lepesant, J-A., Garen, A., Kejzlarova-Lepesant, J., Maschat, F., Rat, L. (1979) Ecdysone inducible functions of larval fat bodies in *Drosophila*. In: *Eucaryotic gene regulation*. 10th I.C.N.-U.C.L.A. Symposium, T. Maniatis, R. and R. Axel, eds. Academic Press, pp. 161-165.
- Simpson, P., Lawrence, P.A., Maschat, F. (1981) Clonal analysis of two wing scalloping mutants of *Drosophila*. . *Develop. Biol.* 84, 206-211.

**Publications en cours:**

- Bonneaud, N., Layalle, S., Colomb, S., Severac, D., Dantec, C., Nègre, N., Maschat. F. "How Engrailed and Gooseberry-Neuro trigger axonal growth and pathfinding to construct a nerve cord". *Article soumis*.

**- Dissémination et valorisation:**

- Maschat F. (2013). [A peptide to treat Huntington's disease. Dans « International Innovation », Issue 119 : Women in Science, pp.74-76.](#)
- «Maladie de Huntington : [Désignation d'un nouveau peptide](#) » [lettre innovation du CNRS 11/06/ 2015.](#)
- « [Huntington : un premier pas vers le développement d'un médicament](#) » Actualités Inserm 2/10/2015.
- « HuntToTreat » projet labellisé par le pôle de compétitivité Eurobiomed. Catalogue (*en cours*).
- Implication dans projet FHU *NEUROCLIN*: « *Neuroscience from Basic Experiments to Clinic* » (*préselectionné*)
- Participation à la labellisation de Montpellier comme «Centre d'excellence en enseignement et recherche sur les maladies neurodégénératives MND».

**- Brevets**

- 2012- ([PCT/FR2012/050809, 04/12/2012](#)). Titre: Composés thérapeutiques contre la chorée de Huntington.
- 2013- Therapeutic peptides and use thereof against Huntington's disease [patent WO 2012140376](#). 4 brevets soumis à l'international (EP12722415.2; US14/111285; CA2832521; AU2012241648).

- **Désignation de médicament orphelin** de « [P42 pour le traitement de la maladie de Huntington](#) ». Sponsor : CNRS- FIST par l'Agence Européenne du médicament (EMA)- Avril 2015. (EMA/COMP/275974/2015).

**- Invitations récentes congrès/séminaires:**

- Fondation des maladies rares: Rencontres de l'innovation (Paris). [«Analyse d'un peptide protecteur de la maladie de Huntington: De son identification chez la drosophile à son utilisation potentielle à des fins thérapeutiques»](#). 31 Mars 2015.
- Enroll-HD site Investigators Meeting- Madrid. 1-2 Octobre 2015 .
- [Les mardis de l'innovation au CNRS. 15 décembre 2015.](#)